OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Progress in the controllability technology of PROTAC
Xin He, Zhibing Weng, Yi Zou
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116096-116096
Closed Access | Times Cited: 17
Xin He, Zhibing Weng, Yi Zou
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116096-116096
Closed Access | Times Cited: 17
Showing 17 citing articles:
Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review)
Guoan Zhang, Sen Hou, Shuyue Li, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 5
Open Access | Times Cited: 11
Guoan Zhang, Sen Hou, Shuyue Li, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 5
Open Access | Times Cited: 11
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 11
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 11
Insights into tumor-derived exosome inhibition in cancer therapy
Ziwei Tang, Cheng Chen, Chen Zhou, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117278-117278
Closed Access | Times Cited: 1
Ziwei Tang, Cheng Chen, Chen Zhou, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117278-117278
Closed Access | Times Cited: 1
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
A Comprehensive Overview of Protacs Targeting Hsp90 and Their Client Proteins for Cancer Therapy
Gulshan Kumar, Gouri Tyagi, Vikramdeep Monga
(2025)
Closed Access
Gulshan Kumar, Gouri Tyagi, Vikramdeep Monga
(2025)
Closed Access
Prodrug Approach as a Strategy to Enhance Drug Permeability
Mariana Moraes Dionysio de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 297-297
Open Access
Mariana Moraes Dionysio de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 297-297
Open Access
From Unwanted Annoyances to Oral Delivery Saviors: The Rollercoaster Journey of Amorphous Drugs
Lynne S. Taylor, George Zografi
Molecular Pharmaceutics (2025)
Closed Access
Lynne S. Taylor, George Zografi
Molecular Pharmaceutics (2025)
Closed Access
The Peptide PROTAC Modality: A New Strategy for Drug Discovery
Youmin Zhu, Yu Dai, Yun-Cai Tian
MedComm (2025) Vol. 6, Iss. 4
Open Access
Youmin Zhu, Yu Dai, Yun-Cai Tian
MedComm (2025) Vol. 6, Iss. 4
Open Access
Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple Negative Breast Cancer Treatment
Hongye He, Feng Li, Rui Tang, et al.
Biomaterials Research (2024) Vol. 2024
Open Access | Times Cited: 3
Hongye He, Feng Li, Rui Tang, et al.
Biomaterials Research (2024) Vol. 2024
Open Access | Times Cited: 3
Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
KLHL20 and its role in cell homeostasis: A new perspective and therapeutic potential
Rolivhuwa Bishop Ramagoma, Lilian Makgoo, Zukile Mbita
Life Sciences (2024) Vol. 357, pp. 123041-123041
Closed Access | Times Cited: 1
Rolivhuwa Bishop Ramagoma, Lilian Makgoo, Zukile Mbita
Life Sciences (2024) Vol. 357, pp. 123041-123041
Closed Access | Times Cited: 1
Development of natural product-based targeted protein degraders as anticancer agents
Cheng Chen, Yanyan Feng, Chen Zhou, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107772-107772
Closed Access | Times Cited: 1
Cheng Chen, Yanyan Feng, Chen Zhou, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107772-107772
Closed Access | Times Cited: 1
Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer
Zhanzhan Feng, Shirui Wang, Su Jong Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116780-116780
Closed Access
Zhanzhan Feng, Shirui Wang, Su Jong Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116780-116780
Closed Access
Toosendanin: upgrade of an old agent in cancer treatment
Shuwei Li, Qingyi Xiong, Yilei Shen, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 10, pp. 887-899
Closed Access
Shuwei Li, Qingyi Xiong, Yilei Shen, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 10, pp. 887-899
Closed Access
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
PROTACs of cyclin-dependent kinases
Denisa Veselá, Eva Řezníčková, Václav Mik, et al.
Annual reports in medicinal chemistry (2024)
Closed Access
Denisa Veselá, Eva Řezníčková, Václav Mik, et al.
Annual reports in medicinal chemistry (2024)
Closed Access
